| Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.PMID 39700442 · J Clin Oncol |
2025-Mar-20 |
1 | 1 | 1 | 2 |
提取完成 |
| Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.PMID 39378385 · J Clin Oncol |
2025-Mar-10 |
1 | 2 | 2 | 8 |
提取完成 |
| Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.PMID 38875119 · Hepatology |
2025-Mar-01 |
2 | 2 | 2 | 4 |
提取完成 |
| Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.PMID 39647999 · J Clin Oncol |
2025-Mar |
1 | 5 | 5 | 11 |
质量警告 |
| Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.PMID 39863775 · Nat Med |
2025-Mar |
1 | 1 | 1 | 1 |
质量警告 |
| Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.PMID 39651791 · N Engl J Med |
2025-Feb-27 |
1 | 6 | 6 | 9 |
质量警告 |
| ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.PMID 39956849 · Signal Transduct Target Ther |
2025-Feb-17 |
2 | 3 | 3 | 5 |
质量警告 |
| Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.PMID 39282913 · N Engl J Med |
2025-Feb-13 |
2 | 2 | 2 | 2 |
质量警告 |
| Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial.PMID 39948076 · Sci Rep |
2025-Feb-13 |
1 | 2 | 2 | 6 |
提取完成 |
| SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.PMID 39671534 · J Clin Oncol |
2025-Feb-10 |
2 | 6 | 6 | 24 |
提取完成 |
| Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity.PMID 39825571 · J Cachexia Sarcopenia Muscle |
2025-Feb |
2 | 8 | 8 | 20 |
提取完成 |
| Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.PMID 39854806 · Gynecol Oncol |
2025-Feb |
2 | 4 | 4 | 7 |
质量警告 |
| The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.PMID 39921934 · ESMO Open |
2025-Feb |
1 | 4 | 4 | 5 |
质量警告 |
| Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.PMID 39250535 · J Clin Oncol |
2025-Jan-20 |
2 | 6 | 6 | 10 |
质量警告 |
| Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.PMID 39265124 · J Clin Oncol |
2025-Jan-20 |
2 | 3 | 3 | 5 |
质量警告 |
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.PMID 39798579 · Lancet |
2025-Jan-18 |
1 | 2 | 2 | 4 |
提取完成 |
| A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.PMID 39540844 · Clin Cancer Res |
2025-Jan-17 |
1 | 1 | 1 | 2 |
提取完成 |
| Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.PMID 39331724 · Blood |
2025-Jan-16 |
1 | 2 | 2 | 6 |
提取完成 |
| A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer.PMID 39800716 · Signal Transduct Target Ther |
2025-Jan-13 |
2 | 2 | 2 | 4 |
提取完成 |
| Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.PMID 39298738 · J Clin Oncol |
2025-Jan-10 |
1 | 3 | 3 | 3 |
质量警告 |
| Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.PMID 39303200 · J Clin Oncol |
2025-Jan-10 |
2 | 4 | 4 | 8 |
提取完成 |
| Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial.PMID 39579142 · JNCI Cancer Spectr |
2025-Jan-03 |
1 | 1 | 1 | 1 |
质量警告 |
| Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.PMID 39282897 · N Engl J Med |
2025-Jan-02 |
2 | 5 | 5 | 15 |
提取完成 |
| Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.PMID 39282902 · N Engl J Med |
2025-Jan-02 |
3 | 4 | 4 | 5 |
质量警告 |
| Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials.PMID 39128018 · J Natl Cancer Inst |
2025-Jan-01 |
1 | 6 | 6 | 12 |
提取完成 |
| Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.PMID 39541202 · JAMA Oncol |
2025-Jan-01 |
2 | 6 | 6 | 19 |
质量警告 |
| Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.PMID 39227450 · Ann Hematol |
2025-Jan |
2 | 2 | 2 | 3 |
质量警告 |
| Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.PMID 39379782 · Breast Cancer |
2025-Jan |
2 | 4 | 4 | 7 |
质量警告 |
| Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.PMID 39442921 · Br J Haematol |
2025-Jan |
1 | 2 | 2 | 15 |
质量警告 |
| Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients.PMID 39754976 · ESMO Open |
2025-Jan |
1 | 2 | 2 | 3 |
质量警告 |